-
Effects of home-based exergaming on cardio-metabolic and cognitive health in physically inactive individuals Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-13 Andreas Melmer, Anna Lisa Martin-Niedecken, Wanda Wehrli, Patrick Lüchinger, Yanick Riederer, Sam Scott, Jordan Pickles, Stephan Niedecken, David Flagmeier, Stephan Villiger, Roman Jurt, Nicole Kind, Lilian Witthauer, Alexandra Schättin, Christoph Stettler
To examine the effects of a home-based exergame training over 6 weeks on cardio-metabolic and cognitive health, as well as training adherence, in physically inactive individuals.
-
Analyses of potential causal contributors to increased waist/hip ratio‐associated cardiometabolic disease: A combined and sex‐stratified Mendelian randomization study Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-16 Habiba Hashemy, Anthony Nguyen, Rana Khafagy, Delnaz Roshandel, Andrew D. Paterson, Satya Dash
BackgroundIncreased waist/hip ratio (WHR) contributes to type 2 diabetes, fatty liver, dyslipidaemia, hypertension and coronary artery disease, with potential sex‐differential effects. Postulated mediators include increased lipid flux, branched‐chain amino acids, glycine and glycoprotein acetyl, but their relative contributions and sex‐specific impact on WHR‐associated cardiometabolic disease (CMD)
-
Personalizing cardiovascular risk: Coronary artery calcium scans to improve statin use in adults with type 2 diabetes can be cost‐effective in select individuals Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-16 Darren Lau, Glen J. Pearson, Paolo Raggi, Scott Klarenbach
1 BACKGROUND Many adults with diabetes are not on a statin.1 A coronary artery calcium (CAC) scan provides a depiction of coronary artery disease and is predictive of cardiovascular (CV) risk. Showing and discussing CAC scan findings with patients has been shown to increase the use of preventive medications.2, 3 Even in trials where CAC-based intervention reduced the use of statins (e.g., due to enrolment
-
Efficacy of 1-hour postload plasma glucose as a suitable measurement in predicting type 2 diabetes and diabetes-related complications: A post hoc analysis of the 30-year follow-up of the Da Qing IGT and Diabetes Study Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-15 Minying Peng, Siyao He, Jinping Wang, Yali An, Xin Qian, Bo Zhang, Lihong Zhang, Bo Chen, Zhiwei Yang, Guangwei Li, Qiuhong Gong
To evaluate whether 1-hour plasma glucose (1hPG) can be a comparable measurement to 2-hour plasma glucose (2hPG) in identifying individuals at high risk of developing diabetes.
-
Oral or injectable semaglutide for the management of type 2 diabetes in routine care: A multicentre observational study comparing matched cohorts Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-13 Gian Paolo Fadini, Benedetta Maria Bonora, Mariangela Ghiani, Roberto Anichini, Elena Melchionda, Bruno Fattor, Stefano Fazion, Giancarla Meregalli, Andrea Giaccari, Angelo Avogaro, Agostino Consoli
To investigate the real-world utilization and comparative clinical outcomes of injectable and oral semaglutide in individuals with type 2 diabetes (T2D) with the aim of enhancing understanding of the practical implications associated with choosing between these formulations.
-
Efficacy of topiramate in reducing second‐generation antipsychotic‐associated weight gain among children: A systematic review and meta‐analysis Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-13 Gabriel P. A. Costa, Vitor R. Y. Moraes, Beatriz R. Assunção, Nora Burns, Sobia Laique, Shreya Sengupta, Akhil Anand, Julio C. Nunes
AimsTo conduct a systematic review and meta‐analysis with the aim of synthesizing existing data on the efficacy and safety of topiramate as an adjunctive treatment for reducing second‐generation antipsychotic (SGA)‐associated weight gain in children aged 4–18 years.MethodsWe conducted a comprehensive search of PubMed, Embase, PsychNet and Web of Science from time of their inception up to 12 February
-
Overweight or obesity, weight variability and the risk of retinopathy in type 1 diabetes Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-12 Thomas Nyström, Mikael Andersson Franko, Johnny Ludvigsson, Marcus Lind, Martina Persson
1 BACKGROUND Retinopathy is the most prevalent microvascular complication of type 1 diabetes (T1D), often present during adolescence and eventually affecting the vast majority of subjects with T1D.1 Retinopathy is associated with significant risks of cardiovascular morbidity and preterm mortality.2 Important risk factors for retinopathy include hyperglycaemia, dyslipidaemia, hypertension, obesity and
-
The association between previous use of anti‐obesity medication and semaglutide weight loss outcomes Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-12 Wissam Ghusn, Sima Fansa, Diego Anazco, Elif Tama, Lizeth Cifuentes, Khushboo Gala, Alan De La Rosa, Daniel Sacoto, Alejandro Campos, Fauzi Feris, Daniela Hurtado, Andres Acosta
AimsTo compare weight loss outcomes between patients starting semaglutide who had previously been on another anti‐obesity medication (AOM) compared to those who were AOM‐naïve.Materials and MethodsWe performed a retrospective study in patients with overweight or obesity taking semaglutide for weight loss for a duration of 3 to 12 months. Our primary endpoint was assessment of percentage of total body
-
Use of once‐daily oral semaglutide and associated clinical outcomes among adults with type 2 diabetes in routine clinical practice in Canada: A multicentre, prospective real‐world study (PIONEER REAL Canada) Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-12 Akshay B. Jain, Sonja M. Reichert, Hanan Amadid, Uffe C. Braae, Ryan M. Bradley, James W. Kim, Victoria Soo, Jean‐François Yale
AimPIONEER REAL Canada examined real‐world clinical outcomes associated with the use of once‐daily oral semaglutide in adults with type 2 diabetes.Materials and MethodsThis was a 34‐ to 44‐week, multicentre, prospective, open‐label, non‐interventional study in adults who were treatment‐naive to injectable glucose‐lowering medication and initiated oral semaglutide in routine clinical practice. The primary
-
The impact of metformin on weight and metabolic parameters in patients with obesity: A systematic review and meta‐analysis of randomized controlled trials Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-12 Rachelle Haber, Fatima Zarzour, Malak Ghezzawi, Natalie Saadeh, Dania S. Bacha, Lama Al Jebbawi, Marlene Chakhtoura, Christos S. Mantzoros
There are conflicting data on the weight‐reducing potential of metformin (MTF) in nondiabetic patients with obesity. The purpose of this systematic review and meta‐analysis was to evaluate the effect of MTF on weight and cardiometabolic parameters in adults with overweight/obesity with or without nonalcoholic fatty liver disease (NAFLD) (CRD42018085512). We included randomized controlled trials (RCTs)
-
Low‐grade inflammation in persons with recently diagnosed type 2 diabetes: The role of abdominal adiposity and putative mediators Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-11 Sidsel L. Domazet, Thomas B. Olesen, Jacob V. Stidsen, Camilla K. Svensson, Jens S. Nielsen, Reimar W. Thomsen, Niels Jessen, Peter Vestergaard, Mette K. Andersen, Torben Hansen, Charlotte Brøns, Verena H. Jensen, Allan A. Vaag, Michael H. Olsen, Kurt Højlund
AimsTo determine the magnitude of the association between abdominal adiposity and low‐grade inflammation in persons with recently diagnosed type 2 diabetes (T2D) and to determine to what extent this association is mediated by low physical activity level, hyperinsulinaemia, hyperglycaemia, dyslipidaemia, hypertension, and comorbidities.Materials and MethodsWe measured waist circumference, clinical characteristics
-
Hydrogel dressings for diabetic foot ulcer: A systematic review and meta‐analysis Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-11 Hongjiao Zhao, You Wu, Yuchen Xie, Yanfei Li, Chen Chen, Chanjuan Li, Fangzheng Yang, Deteng Zhang, Yaqin Wang, Junhua Yuan
AimTo investigate the differences in utility between conventional dressings and hydrogel dressings for the treatment of diabetic foot ulcer (DFU).MethodsThe PubMed, Embase, Cochrane Library, CNKI, VIP and Wanfang databases were systematically searched up to 21 January 2023. Fixed/random‐effect models were used to calculate the odds ratios (ORs) and mean differences (MDs) with 95% confidence intervals
-
Lifetime and 10‐year cardiovascular risk prediction in individuals with type 1 diabetes: The LIFE‐T1D model Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-08 Marga A. G. Helmink, Steven H. J. Hageman, Björn Eliasson, Naveed Sattar, Frank L. J. Visseren, Jannick A. N. Dorresteijn, Katie Harris, Sanne A. E. Peters, Mark Woodward, Péter Szentkúti, Kurt Højlund, Jan Erik Henriksen, Henrik Toft Sørensen, Erik H. Serné, Thomas T. van Sloten, Reimar W. Thomsen, Jan Westerink
AimsTo develop and externally validate the LIFE‐T1D model for the estimation of lifetime and 10‐year risk of cardiovascular disease (CVD) in individuals with type 1 diabetes.Materials and MethodsA sex‐specific competing risk‐adjusted Cox proportional hazards model was derived in individuals with type 1 diabetes without prior CVD from the Swedish National Diabetes Register (NDR), using age as the time
-
Effect of tirzepatide on the risk of diabetic retinopathy in type 2 diabetes Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-08 Djordje S. Popovic, Dimitrios Patoulias, Paschalis Karakasis, Theocharis Koufakis, Nikolaos Papanas
CONFLICT OF INTEREST STATEMENT None to declare.
-
A 52‐week efficacy and safety study of enavogliflozin versus dapagliflozin as an add‐on to metformin in patients with type 2 diabetes mellitus: ENHANCE‐M extension study Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-08 Tae Seo Sohn, Kyung‐Ah Han, Yonghyun Kim, Byung‐Wan Lee, Suk Chon, In‐Kyung Jeong, Eun‐Gyoung Hong, Jang Won Son, JaeJin Na, Jae Min Cho, Seong In Cho, Wan Huh, Kun‐Ho Yoon
AimTo evaluate the long‐term safety and efficacy of enavogliflozin 0.3 mg/day added to metformin in patients with type 2 diabetes mellitus.Materials and MethodsAfter 24 weeks of a randomized, double‐blind treatment period with enavogliflozin 0.3 mg/day (n = 101) or dapagliflozin 10 mg/day (n = 99) added to metformin, all patients received enavogliflozin 0.3 mg/day plus metformin for an additional 28
-
Sex‐specific associations between haemoglobin glycation index and the risk of cardiovascular and all‐cause mortality in individuals with pre‐diabetes and diabetes: A large prospective cohort study Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-08 Jingqi Yang, Qing Shangguan, Guobo Xie, Ming Yang, Guotai Sheng
AimThe aim of this study was to investigate the relationship between the haemoglobin glycation index (HGI), and cardiovascular disease (CVD) and all‐cause mortality in adults with pre‐diabetes and diabetes.MethodsThis study included 10 267 adults with pre‐diabetes and diabetes from the National Health and Nutrition Examination Survey (NHANES) 1999‐2018. Sex‐differentiated relationships between HGI
-
Ingesting probiotic yogurt containing Lactiplantibacillus plantarum OLL2712 improves glycaemic control in adults with prediabetes in a randomized, double-blind, placebo-controlled trial Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-07 Takayuki Toshimitsu, Ayako Gotou, Toshihiro Sashihara, Kenichi Hojo, Satoshi Hachimura, Nobuhiko Shioya, Yoshitaka Iwama, Junichiro Irie, Yoshitatsu Ichihara
The ingestion of Lactiplantibacillus plantarum OLL2712 (OLL2712) cells has been shown to improve glucose metabolism by suppressing chronic inflammation in murine models and clinical studies. This study aimed to clarify the effect of OLL2712 on glycaemic control in healthy adults with prediabetes.
-
Acquired hypothalamic obesity: A clinical overview and update Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-07 Christian L. Roth, Shana E. McCormack
Hypothalamic obesity (HO) is a rare and complex disorder that confers substantial morbidity and excess mortality. HO is a unique subtype of obesity characterized by impairment in the key brain pathways that regulate energy intake and expenditure, autonomic nervous system function, and peripheral hormonal signalling. HO often occurs in the context of hypothalamic syndrome, a constellation of symptoms
-
Performance of new and panel CKD‐EPI equations in European adults with type 2 diabetes Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-07 Esben Iversen, Katrine McLain Christensen, Anne Byriel Walls, Mie Klessen Eickhoff, Bernt Johan von Scholten, Marie Frimodt‐Møller, Tine Willum Hansen, Frederik Persson, Peter Rossing, Viktor Rotbain Curovic, Morten Baltzer Houlind
1 BACKGROUND Chronic kidney disease (CKD) is a common complication of type 2 diabetes (T2D) characterized by albuminuria and a progressive decline in the glomerular filtration rate (GFR).1 CKD in the setting of T2D can be the result of diabetic nephropathy, non-diabetic renal disease, or a combination of these factors.2 Regardless of the aetiology, early diagnosis of CKD enables interventions to slow
-
Glucagon‐like peptide‐1 receptor agonists and mental health: A meta‐analysis of randomized controlled trials Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-07 Giovanni Antonio Silverii, Christian Marinelli, Edoardo Mannucci, Francesco Rotella
CONFLICT OF INTERESTS STATEMENT GAS has received financial support and speaking fees from Astra Zeneca, Eli Lilly and Novo Nordisk outside the present paper; EM has received speaking fees from Astra Zeneca, Eli Lilly, Merck, Novo Nordisk and Sanofi, research grants from Eli Lilly and Novo Nordisk, outside the present paer; CM and FR have no conflict of interest to declare.
-
The role of real‐time continuous glucose monitoring in diabetes management and how it should link to integrated personalized diabetes management Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-05 Monika Reddy, Nick Oliver
Diabetes is a complex metabolic condition that demands tailored, individualized approaches for effective management. Real‐time continuous glucose monitoring (rtCGM) systems have improved in terms of design, usability and accuracy over the years and play a pivotal role in the delivery of integrated personalized diabetes management (iPDM). iPDM is a comprehensive multidisciplinary approach that combines
-
-
Associations of diabesity with all‐cause and cardiovascular disease mortality: Findings from the Mexico City Prospective Study Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-05 Fanny Petermann‐Rocha, Evelia Apolinar, Gabriela Nazar, Felipe Diaz‐Toro, Andrés Celis, Salil Deo, Gerson Ferrari, Gary O'Donovan
AimTo investigate the joint associations of diabetes and obesity with all‐cause and cardiovascular disease (CVD) mortality in the Mexico City Prospective Study.Materials and MethodsIn total, 154 128 participants (67.2% women) were included in this prospective analysis. Diabetes was self‐reported, while body mass index was used to calculate obesity. Using diabetes and obesity classifications, six groups
-
A look at duodenal mucosal resurfacing: Rationale for targeting the duodenum in type 2 diabetes Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-04 Jonah A. Hoyt, Emily Cozzi, David A. D'Alessio, Chris C. Thompson, Vanita R. Aroda
Affecting 5%–10% of the world population, type 2 diabetes (T2DM) is firmly established as one of the major health burdens of modern society. People with T2DM require long‐term therapies to reduce blood glucose, an approach that can mitigate the vascular complications. However, fewer than half of those living with T2DM reach their glycaemic targets despite the availability of multiple oral and injectable
-
Pre‐dinner walks may be superior to post‐dinner walks for glucose time in range in adults with type 1 diabetes on hybrid closed‐loop insulin delivery systems Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-04 Lauren V. Turner, Michael C. Riddell
1 INTRODUCTION Individuals with type 1 diabetes (T1D) often experience elevated blood glucose levels after a meal, which can lead to long-term complications, including microvascular or macrovascular disease.1, 2 Previous studies have shown that light to moderate intensity activity post-meal can reduce glucose levels in individuals with T1D.3-5 However, these studies were limited to morning post-meal
-
Accelerated onset of diabetes in non‐obese diabetic mice fed a refined high‐fat diet Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-04 Heidi M. Batdorf, Luz de Luna Lawes, Gabrielle A. Cassagne, Molly S. Fontenot, Innocence C. Harvey, Jeremy T. Richardson, David H. Burk, Samuel D. Dupuy, Michael D. Karlstad, J. Michael Salbaum, Jaroslaw Staszkiewicz, Robbie Beyl, Sujoy Ghosh, Susan J. Burke, J. Jason Collier
AimType 1 diabetes results from autoimmune events influenced by environmental variables, including changes in diet. This study investigated how feeding refined versus unrefined (aka ‘chow’) diets affects the onset and progression of hyperglycaemia in non‐obese diabetic (NOD) mice.MethodsFemale NOD mice were fed either unrefined diets or matched refined low‐ and high‐fat diets. The onset of hyperglycaemia
-
Retinal vascular density as a potential biomarker of diabetic cerebral small vessel disease Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-04 Yinqiong Huang, Siyun Wang, Chi Cai, Xinwei Huang, Yan Chen, Xiaohong Wu, Yiping Zhang, Yan Zhang, Xiahong Lin
AimThe retina and brain share similar anatomical and physiological features. Thus, retinal imaging by optical coherence tomography angiography (OCTA) might be a potential tool for the early diagnosis of diabetic cerebral small vessel disease (CSVD). In this study, we aimed to evaluate retinal vascular density (VD) in diabetic CSVD by OCTA imaging and explore the associations between retinal VD and
-
Testosterone therapy reduces insulin resistance in men with adult‐onset testosterone deficiency and metabolic syndrome. Results from the Moscow Study, a randomized controlled trial with an open‐label phase Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-04 Yuliya Tishova, Svetlana Kalinchenko, George Mskhalaya, Geoffrey Hackett, Mark Livingston, Carola König, Richard Strange, Michael Zitzmann, Amar Mann, Amro Maarouf, Sudarshan Ramachandran
AimsTo describe changes in homeostasis model assessment of insulin resistance index (HOMA‐IR) following testosterone therapy in men with hypogonadism and metabolic syndrome (MetS).Materials and MethodsA randomized, placebo‐controlled, double‐blind randomized controlled trial (RCT) comprising 184 men with MetS and hypogonadism (testosterone undecanoate [TU]: 113 men, placebo: 71 men) was conducted.
-
-
A multicentre, double‐blind, placebo‐controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add‐on therapy in type 2 diabetic patients treated with metformin and dapagliflozin Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-01 Soo Lim, Seung‐Hwan Lee, Kyung‐Wan Min, Chang Beom Lee, Sang Yong Kim, Hye Jin Yoo, Nan Hee Kim, Jae Hyeon Kim, Seungjoon Oh, Jong Chul Won, Hyuk Sang Kwon, Mi Kyung Kim, Jung Hwan Park, In‐Kyung Jeong, Sungrae Kim
AimTo investigate the efficacy and safety of pioglitazone compared to placebo when added to metformin plus dapagliflozin, a sodium‐glucose cotransporter‐2 (SGLT2) inhibitor, for patients with type 2 diabetes mellitus (T2DM).Materials and MethodsIn a multicentre study, with a randomized, double‐blind, placebo‐controlled design, 249 Korean patients with T2DM suboptimally managed on metformin and dapagliflozin
-
Assessing the potential for precision medicine in body weight reduction with regard to type 2 diabetes mellitus therapies: A meta‐regression analysis of 120 randomized controlled trials Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-01 Kris G. Vargas, Tobias Rütten, Benedikt Siemes, Maximilian Brockmeyer, Claudio Parco, Alexander Hoss, Sabrina Schlesinger, Christian Jung, Michael Roden, Malte Kelm, Georg Wolff, Oliver Kuss
AimsTo assess the potential for precision medicine in type 2 diabetes by quantifying the variability of body weight as response to pharmacological treatment and to identify predictors which could explain this variability.MethodsWe used randomized clinical trials (RCTs) comparing glucose‐lowering drugs (including but not limited to sodium‐glucose cotransporter‐2 inhibitors, glucagon‐like peptide‐1 receptor
-
Blood glucose control using a mobile health application in Singapore, Philippines and Hong Kong: a retrospective real‐world data analysis Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-02-29 Yi Hui Tan, Wen Lee Tan, Valerie Eichinger, Bernhard Ruch, Ester Yeoh
CONFLICT OF INTEREST STATEMENT WLT is an employee of Roche Diabetes Care Asia Pacific Pte Ltd. VE and BR are employees of mySugr GmbH. YHT and EY have no conflicts of interest to declare.
-
Real‐world glycated haemoglobin changes among type 2 diabetes mellitus patients treated with a maintenance dose of 7 mg or 14 mg of oral semaglutide Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-02-29 Caroline Swift, Monica Frazer, Noelle N. Gronroos, Andrew Sargent, Michael Leszko, Erin Buysman, Sara Alvarez, Tyler J. Dunn, Josh Noone, Mico Guevarra
AimTo describe the change in glycated haemoglobin (HbA1c) among patients with type 2 diabetes following treatment with a 7 or 14 mg maintenance dose of oral semaglutide.Materials and MethodsThis retrospective, claims‐based study included adult patients with type 2 diabetes with a pre‐index HbA1c of ≥7%, initiating treatment with oral semaglutide between 1 November 2019 and 30 June 2020; the patients
-
Pharmacological treatment of obesity in adults in Norway 2004–2022 Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-02-29 Paz Lopez‐Doriga Ruiz, Øystein Karlstad, Kjersti Nøkleby, Kristina Slåtsve, Hanne L. Gulseth, Haakon E. Meyer, Kari Anne Sveen, Elisabeth Qvigstad, Kari Furu
AimsTo describe trends in the use of anti‐obesity drugs in Norway during the period 2004–2022.Materials and MethodsWe assessed the annual utilization of any available drug indicated for obesity recorded in the nationwide Norwegian Prescribed Drug Register for adults (age 18–79 years) from 1 January 2004 to 31 December 2022. Prevalence was stratified by sex and age group (18–29 years and 10‐year age
-
Insulin resistance before type 2 diabetes onset is associated with increased risk of albuminuria after diabetes onset: A prospective cohort study Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-02-29 Meeah R. Willig, Emma J. Stinson, Helen C. Looker, Paolo Piaggi, Cassie M. Mitchell, Robert L. Hanson, Robert G. Nelson, Jonathan Krakoff, Douglas C. Chang
AimReduced renal insulin signalling is implicated in the pathogenesis of albuminuria. We sought to investigate whether insulin action and secretion, measured before diabetes onset, are associated with the development of albuminuria after diabetes onset.Materials and MethodsBaseline body composition, insulin sensitivity by hyperinsulinaemic‐euglycaemic clamp at submaximal and maximal insulin stimulation
-
Associations of body mass index trajectory, waist circumference trajectory, or both with type 2 diabetes mellitus risk in Chinese adults: The China‐PAR project Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-02-29 Yang Zhao, Minghui Han, Ranran Qie, Yanyan Zhang, Yuying Wu, Xueru Fu, Dongdong Zhang, Lei Kuang, Pei Qin, Fulan Hu, Jianxin Li, Xiangfeng Lu, Dongsheng Hu, Ming Zhang
AimsTo identify the trajectories of body mass index (BMI) and waist circumference (WC), and assess the associations of BMI trajectory, WC trajectory, or the two combined, with type 2 diabetes mellitus (T2DM) risk in Chinese adults.Materials and MethodsThis study was based on a prospective project—the Prediction for Atherosclerotic Cardiovascular Disease Risk in China (China‐PAR). A total of 54 434
-
The number of nephroprotection targets attained is associated with cardiorenal outcomes and mortality in patients with diabetic kidney disease. The CKD‐REIN cohort study Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-02-29 Fabrice Bonnet, Beverley Balkau, Oriane Lambert, Yakhara Diawara, Christian Combe, Luc Frimat, Maurice Laville, Sophie Liabeuf, Ziad A. Massy, Marie Metzger, Bénédicte Stengel, Natalia Alencar de Pinho, Denis Fouque
AimThe risk of cardiorenal events remains high among patients with diabetes and chronic kidney disease (CKD), despite the prescription of recommended treatments. We aimed to determine whether the attainment of a combination of nephroprotection targets at baseline (glycated haemoglobin <7.0%, urinary albumin‐creatinine ratio <300 mg/g, blood pressure <130/80 mmHg, renin‐angiotensin system inhibition)
-
Bridging dose of U‐100 glargine with first dose of insulin degludec improves glycaemia in the 48 h after transition in twice‐daily glargine users Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-02-29 Arthi Thirumalai, Jing H. Chao, Thanmai Kaleru, Xiaofu Dong, Patali Mandava, Dori Khakpour, Irl B. Hirsch
AimsTo study the effects of a bridging dose of U‐100 glargine (U‐100G) with the first dose of degludec in type 1 diabetes (T1D) patients transitioning from glargine to degludec, by comparing the glucose metrics 48 h before and after the transition.Materials and MethodsPatients with T1D on a stable U‐100G regimen and with glycated haemoglobin concentration <75 mmol/mol were randomized (double‐blind)
-
Renal outcomes with sodium‐glucose cotransporter 2 inhibitors in Japanese people with grade 3 chronic kidney disease and type 2 diabetes: Analysis of medical administrative databases Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-02-28 Hiroaki Iijima, Maki Gouda, Hideaki Hida, Kazumi Mori‐Anai, Akiko Takahashi, Ryoichi Minai, Hideki Ninomiya, Yoshiyuki Saito, Atsushi Miyawaki, Jun Wada
AimTo evaluate whether sodium‐glucose cotransporter 2 inhibitor (SGLT2i) therapy is associated with a reduction of renal events compared with other glucose‐lowering drugs (oGLDs) among Japanese people with type 2 diabetes (T2D) and grade 3 (G3) chronic kidney disease (CKD) in a real‐world clinical practice setting.Materials and MethodsPeople with T2D who were newly prescribed an SGLT2i or an oGLD from
-
Associations of a proinflammatory diet, habitual salt intake, and the onset of type 2 diabetes: A prospective cohort study from the UK Biobank Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-02-26 Wenqi Shen, Lingli Cai, Bin Wang, Jiang Li, Ying Sun, Yi Chen, Fangzhen Xia, Ningjian Wang, Yingli Lu
To explore the relationship between proinflammatory diet, habitual salt intake and the onset of type 2 diabetes.
-
Clinically relevant stratification of patients with type 2 diabetes by using continuous glucose monitoring data Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-02-26 Xiaopeng Shao, Jingyi Lu, Rui Tao, Liang Wu, Yaxin Wang, Wei Lu, Hongru Li, Jian Zhou, Xia Yu
The wealth of data generated by continuous glucose monitoring (CGM) provides new opportunities for revealing heterogeneities in patients with type 2 diabetes mellitus (T2DM). We aimed to develop a method using CGM data to discover T2DM subtypes and investigate their relationship with clinical phenotypes and microvascular complications.
-
Does metformin reduce the risk of cancer in obesity and diabetes? A systematic review and meta‐analysis Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-02-23 Leonardo A. Mesquita, Bernardo F. Spiazzi, Giovana F. Piccoli, Daniela A. Nogara, Gabriella R. da Natividade, Henrique I. Garbin, Laura F. Wayerbacher, Vanessa M. Wiercinski, Viviane A. Baggio, Carolina P. Zingano, Gilberto Schwartsmann, Gilberto Lopes, John R. Petrie, Verônica Colpani, Fernando Gerchman
AimTo evaluate the effect of metformin on cancer incidence in subjects with overweight/obesity and/or prediabetes/diabetes.Materials and MethodsWe searched MEDLINE, Embase and CENTRAL for randomized controlled trials (RCTs) in adults with overweight/obesity and/or prediabetes/diabetes that compared metformin to other interventions for ≥24 weeks. Independent reviewers selected and extracted data including
-
Bardet-Biedl syndrome: A clinical overview focusing on diagnosis, outcomes and best-practice management Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-02-21 Ashley Shoemaker
Bardet-Biedl syndrome (BBS) is a genetic disorder characterized by early-onset obesity, polydactyly, genital and kidney anomalies, developmental delay and vision loss due to rod-cone dystrophy. BBS is an autosomal recessive disorder with >20 implicated genes. The genotype–phenotype relationship in BBS is not clear, and there may be additional modifying factors. The underlying mechanism is dysfunction
-
Pharmacokinetic and pharmacodynamic properties of once-weekly insulin icodec in individuals with type 1 diabetes Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-02-20 Ulrike Hövelmann, Susanne Engberg, Tim Heise, Niels Rode Kristensen, Lea Nørgreen, Eric Zijlstra, Rasmus Ribel-Madsen
To investigate the pharmacokinetic/pharmacodynamic properties of once-weekly insulin icodec in individuals with type 1 diabetes (T1D).
-
Insulin glargine 300 U/ml versus insulin degludec 100 U/ml improves nocturnal glycaemic control and variability in type 1 diabetes under routine clinical practice: A glucodensities-based post hoc analysis of the OneCare study Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-02-20 Fernando Gomez-Peralta, Ana Chico Ballesteros, Amparo Marco Martínez, Begoña Pérez Corral, Ignacio Conget Donlo, Paulina Fuentealba Melo, Fernando Zaragozá Arnáez, Marcos Matabuena Rodríguez
1 BACKGROUND Long-term micro- and macrovascular complications are the main cause of disability and mortality in people with type 1 diabetes (T1D). In the Diabetes Control and Complications Trial (DCCT), intensive insulin treatment improving glycaemic control was associated with a 50%-76% reduction in the onset and progression of microvascular complications.1 International guidelines recommend close
-
TEAD1, MYO7A and NDUFC2 are novel functional genes associated with glucose metabolism in BXD recombinant inbred population Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-02-22 Yingying Wu, Chao Zhang, Shaofei Duan, Yushan Li, Lu Lu, Akhilesh Bajpai, Chunhua Yang, Jia Mi, Geng Tian, Fuyi Xu, Donglai Qi, Zhaowei Xu, Xiao Dong Chi
AimThe liver is an important metabolic organ that governs glucolipid metabolism, and its dysfunction may cause non‐alcoholic fatty liver disease, type 2 diabetes mellitus, dyslipidaemia, etc. We aimed use systematic investigation of the key factors related to hepatic glucose metabolism, which may be beneficial for understanding the underlying pathogenic mechanisms for obesity and diabetes mellitus
-
Association of serum magnesium with metabolic syndrome and the role of chronic kidney disease: A population-based cohort study with Mendelian randomization Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-02-16 Nuha Shugaa Addin, Fiona Niedermayer, Barbara Thorand, Jakob Linseisen, Jochen Seissler, Annette Peters, Susanne Rospleszcz
To assess the association of serum magnesium with prevalent and incident metabolic syndrome (MetS) and its individual components in the general population and to examine any effect modification by chronic kidney disease (CKD) status.
-
Digital healthcare solutions to better achieve the weight loss outcomes expected by payors and patients Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-02-21 Louis Talay, Omar Alvi
-
Evaluating different low‐density lipoprotein cholesterol thresholds to initiate statin for prevention of cardiovascular diseases in patients with type 2 diabetes mellitus: A target trial emulation study Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-02-21 Eric Yuk Fai Wan, Wanchun Xu, Anna Hoi Ying Mok, Weng Yee Chin, Esther Yee Tak Yu, Celine Sze Ling Chui, Esther Wai Yin Chan, Ian Chi Kei Wong, Cindy Lo Kuen Lam, Goodarz Danaei
AimThe present study aimed to evaluate the effect of statin therapy for primary prevention of cardiovascular diseases (CVDs) when initiating therapy at different baseline low‐density lipoprotein cholesterol (LDL‐C) levels in patients with type 2 diabetes mellitus (T2DM).Materials and MethodsUsing territory‐wide public electronic medical records in Hong Kong, we emulated a sequence of trials on patients
-
Geographic and ethnicity variation in the prevalence of middle‐aged and elderly adult obesity in China in 2020 Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-02-21 Wen‐Jun Tu, Zhenping Zhao, Feng Yan, Xianwei Zeng, Jilai Li
AimThe objective of this study is to evaluate the mean body mass index (BMI), general obesity and abdominal obesity in adults aged ≥40 years residing in China in 2020, and to analyse variations in these factors across different geographic areas and subpopulations.MethodsWe utilized data from the National Stroke High‐Risk Population Screening programme to calculate and compare the mean BMI and prevalence
-
Comparative analysis of hospitalization risk for incident heart failure in non-Hispanic Black versus non-Hispanic White individuals with type 2 diabetes on empagliflozin (Empa-AA): Insights from real-world data Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-02-15 Basem M. Mishriky, Doyle M. Cummings, Yuanyuan Fu, Jacqueline R. Halladay, Schuyler Jones, Andrea D. Boan, Sara Jones, Shivajirao P. Patil, James R. Powell, Alyssa Adams, William Irish
There are limited data to evaluate hospitalization for heart failure (hHF) in non-Hispanic Black (hereafter Black) or non-Hispanic White (hereafter White) individuals without previous hHF. Our goal was to evaluate the risk of hHF among Black versus White patients with type 2 diabetes (T2DM) who were initially prescribed empagliflozin using real-world data.
-
Insights into the impact of sodium-glucose cotransporter 2 inhibition on urinary tract malignancy: A two-sample Mendelian randomization Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-02-14 Zeyu Han, Yazhou He, Xue Li, Sheyu Li, Jianzhong Ai
CONFLICT OF INTEREST STATEMENT The authors have no conflicts of interest to declare.
-
Hypothalamic control of body fat mass by food intake: The key to understanding why obesity should be treated as a disease Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-02-14 Jonathan Q. Purnell, Carel W. le Roux
Hypothalamic centres have been recognized to play a central role in body weight regulation for nearly 70 years.
-
Association of carpal tunnel syndrome with incident diabetes Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-02-14 Jeppe Ravn Jacobsen, Lucas Malta Westergaard, Emil L. Fosbøl, Søren L. Kristensen, Lars Køber, Frederik Persson, Peter Rossing, Rasmus Rørth
CONFLICT OF INTEREST STATEMENT The authors have no conflicts of interest to declare.
-
County-level socio-environmental factors and obesity prevalence in the United States Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-02-14 Pedro R. V. O. Salerno, Alice Qian, Weichuan Dong, Salil Deo, Khurram Nasir, Sanjay Rajagopalan, Sadeer Al-Kindi
To investigate high-risk sociodemographic and environmental determinants of health (SEDH) potentially associated with adult obesity in counties in the United States using machine-learning techniques.
-
Impact of an online nutrition management application service on glycaemic management in individuals with diabetes: A propensity-score-matched retrospective cohort study Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-02-14 Junya Hironaka, Hiroshi Okada, Megumi Minamida, Yuriko Kondo, Hanako Nakajima, Saori Majima, Noriyuki Kitagawa, Takuro Okamura, Takafumi Senmaru, Emi Ushigome, Naoko Nakanishi, Kazuki Hamada, Tetsuya Nojiri, Masahide Hamaguchi, Michiaki Fukui
To assess the impact of ‘Oishi Kenko’, a nutrition management application (app), on glycaemic control in patients with diabetes.
-
What is meant by ‘integrated personalized diabetes management’: A view into the future and what success should look like Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-02-08 Nick Guldemond
Integrated personalized diabetes management (IPDM) has emerged as a promising approach to improving outcomes in patients with diabetes mellitus (DM). This care approach emphasizes the integration and coordination of different providers, including physicians, nurses, dietitians, social workers and pharmacists. The goal of IPDM is to provide patients with personalized care that is tailored to their needs
-
IDegLira for the real-world treatment of type 2 diabetes in Italy. Final results from the REX observational study Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-02-08 Gian Paolo Fadini, Raffaella Buzzetti, Dario Pitocco, Elena Tortato, Alessia Scatena, Olga Lamacchia, Giusi Lastoria, Lucia Simoni, Agostino Consoli
The study was designed to generate real-world evidence on IDegLira in the Italian clinical practice in two groups of patients with type 2 diabetes (T2D), switching to IDegLira either from a basal only (basal group) or basal-bolus insulin regimen (BB group).
-
Inter-relationships between cardiovascular, renal and metabolic diseases: Underlying evidence and implications for integrated interdisciplinary care and management Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-02-08 Jiten Vora, David Cherney, Mikhail N. Kosiborod, Jonas Spaak, Naresh Kanumilli, Kamlesh Khunti, Carolyn S. P. Lam, Michael Bachmann, Peter Fenici
Cardiovascular, renal and metabolic (CaReMe) diseases are individually among the leading global causes of death, and each is associated with substantial morbidity and mortality. However, as these conditions commonly coexist in the same patient, the individual risk of mortality and morbidity is further compounded, leading to a considerable healthcare burden. A number of pathophysiological pathways are
-
ACAD10 is not required for metformin's metabolic actions or for maintenance of whole-body metabolism in C57BL/6J mice Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-02-13 Michael J. Yew, Sarah E. Heywood, Joe Ng, Olivia M. West, Martin Pal, Andrew Kueh, Graeme I. Lancaster, Stephen Myers, Christine Yang, Yingying Liu, Saskia Reibe, Natalie A. Mellett, Peter J. Meikle, Mark A. Febbraio, David W. Greening, Brian G. Drew, Darren C. Henstridge
Acyl-coenzyme A dehydrogenase family member 10 (ACAD10) is a mitochondrial protein purported to be involved in the fatty acid oxidation pathway. Metformin is the most prescribed therapy for type 2 diabetes; however, its precise mechanisms of action(s) are still being uncovered. Upregulation of ACAD10 is a requirement for metformin's ability to inhibit growth in cancer cells and extend lifespan in Caenorhabditis